Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Read full articleEli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Written on 04/20/2026

